Allogeneic Stem Cell Transplantation in Multiple Myeloma: Risk Factors and Outcomes in the Era of New Therapeutic Options-A Single-Center Experience.

Irene StrasslAlexander NikoloudisSigrid Machherndl-SpandlVeronika Buxhofer-AuschMichaela BinderDagmar WipplingerOlga StiefelEmine KaynakRobert MilanovChristoph AichingerStefanie NockerThomas BauerStefanie KreisslMichael GirschikofskyAndreas PetzerAnsgar WeltermannJohannes Clausen

Published in: Cancers (2023)

For selected patients, allo-HSCT may result in favorable overall survival, in part by providing an appropriate hemato-immunological basis for subsequent therapies.

Keyphrases

stem cell transplantation
high dose
risk factors
end stage renal disease
multiple myeloma
ejection fraction
newly diagnosed
chronic kidney disease
bone marrow
prognostic factors
peritoneal dialysis
low dose
hematopoietic stem cell
adipose tissue
metabolic syndrome
weight loss
free survival